产品中心 药物靶点和Fc受体 药物靶点

所有图片(1/2)

GCGR His Tag Protein, Human

价格 6,800.00 供应商现货 : 3-5个工作日
货号 UA010052
规格
数量
收藏 分享

关联产品推荐

产品介绍 评论(0)

产品规格
  • 物种

    Human
  • Accession

    P47871-1
  • 表达序列

    Ala26-Lys136, with C-terminal 8*His
  • 表达宿主

    HEK293
  • 分子量

    33-43 kDa(Reducing)

  • 纯度

    >95% by SDS-PAGE

  • 内毒素含量

    <0.1EU/μg
  • 标记

    Unconjugated
  • 标签

    His Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, pH7.4
  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.
    · Please avoid repeated freeze-thaw cycles.
背景介绍
  • The glucagon receptor (GCGR) is a Class B GPCR that has an important role in maintenance of glucose homeostasis and, as such, is considered to be a valuable target for the treatment of diabetes. The GCGR is widely expressed and can be found in the liver, adipose tissue, heart, kidney, pancreatic islets, stomach, small intestine, thyroid, and skeletal muscle. The GCGR is coupled to the activation of adenylate cyclase via Gs, with concomitant rise in cellular cyclic AMP levels and activation of protein kinase A (PKA). GCGR mRNA has been detected in islets. In vitro/ex vivo studies suggest that glucagon potentiates insulin secretion from isolated islets, although the potency is considerably less than that of the insulin secretagogue GLP-1. Mutations of the GCGR gene are associated with congenital noninsulin-dependent diabetes, and inhibition of GCGR in vivo lowers blood glucose and improves glucose tolerance in obese diabetic mice.

  • 电泳

    • 2μg (R: reducing conditions, N: non-reducing conditions).
  • ELISA

    • Immobilized Crotedumab (Cat. No. UA011042) at 2.0μg/mL (100μL/well) can bind GCGR His Tag Protein, Human(Cat. No. UA010052) with EC50 of 3.54-3.92ng/ mL.

评论(0)